Analytical Data
-
Gene name
IL-1R2
-
简介
IL-1R2 is a competitive endogenous inhibitor of IL-1 signaling. IL-1R2 serves as a decoy receptor and competes with IL-1R1 for IL-1, it can also form a complex with IL-1RAP once it binds IL-1. IL-1R2 is implicated in various IL-1-mediated inflammatory diseases[1]. IL-1R2 Protein, Human (HEK293, Fc) is a recombinant human IL-1R2 protein with an hFc tag at the C-terminus and is expressed in HEK293 cells. It consists of 330 amino acids (F14-E343).
- Application
-
Alternative Names
IL-1R-2; IL-1RT-2; IL-1RT2; CDw121b; IL-1R-beta; CD121b; IL1RB; IL1R2; IL-1 RII; MGC47725
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P27930
-
Expression Region
F14-E343
-
Protein Length
Extracellular Domain
-
Molecular Weight
70-80 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-1 receptor type 2 (IL-1R2) is a crucial component of the interleukin-1 (IL-1) signaling pathway, which plays a significant role in the immune response and inflammation. As a decoy receptor, IL-1R2 binds to IL-1α and IL-1β, preventing their interaction with the signal-transducing receptor IL-1R1, thereby inhibiting pro-inflammatory signaling. This unique functionality positions IL-1R2 as a potential therapeutic target for various inflammatory and autoimmune diseases, such as rheumatoid arthritis, sepsis, and other chronic inflammatory conditions. Research on recombinant IL-1R2 proteins has gained traction, focusing on their role as anti-inflammatory agents. Studies have demonstrated that the recombinant protein can effectively reduce inflammation by blocking IL-1 mediated signaling pathways, leading to decreased cytokine production and immune cell activation. Additionally, understanding the structural and functional characteristics of IL-1R2 has paved the way for the development of novel therapeutic strategies, including the design of IL-1R2 fusion proteins or monoclonal antibodies that can enhance its efficacy. The potential application of IL-1R2 in clinical settings is significant as it opens new avenues for treatment, highlighting the importance of ongoing research to fully elucidate its mechanisms, optimize rescue strategies, and assess its effectiveness in human disease models. Consequently, recombinant IL-1R2 proteins not only present a promising landscape in immunological research but also hold transformative potential in therapeutic interventions aimed at managing acute and chronic inflammatory disorders.
